Cell-Penetrating Peptides Deliver Gene-Silencing Therapy to Shrink Aggressive Breast Cancer Tumors

The researchers synthesized four CPP:siRNA nanocomplexes and characterized their physicochemical properties (size, uniformity). They tested delivery efficiency and gene-silencing activity in TNBC cell lines in vitro. Clonogenic assays assessed whether LDHC silencing improved sensitivity to olaparib. In vivo anti-tumor activity was evaluated using a TNBC zebrafish xenograft model, which allows rapid assessment of tumor growth and treatment safety.

Triple-negative breast cancer has the fewest treatment options of any breast cancer subtype. LDHC is a particularly attractive target because it is almost exclusively expressed in tumor cells — not in normal tissues — which should minimize side effects. Cell-penetrating peptides offer a drug delivery solution for targets like LDHC where no small-molecule inhibitors exist. This combination of precise target and peptide-based delivery could open new therapeutic avenues for TNBC.

Cell-penetrating peptides are emerging as a versatile platform for delivering therapeutic molecules that can't reach their targets on their own. This study demonstrates their potential in cancer therapy by combining CPPs with gene-silencing technology (siRNA) to target a tumor-specific gene. As peptide delivery technology advances, this approach could be applied to many other cancer targets where traditional drugs have failed.

The in vivo testing was limited to zebrafish xenograft models, which are useful for rapid screening but don't fully replicate human tumor biology or drug metabolism. The abstract appears to have incomplete data (truncated results section). No mammalian in vivo models were used, and human clinical translation would require extensive additional testing. The long-term stability and efficacy of CPP:siRNA complexes in more complex biological environments remain unknown.